- RecruitingPHASE3
A Study of Pitolisant in Patients With Prader-Willi Syndrome
This study is testing a medication called Pitolisant for people aged 6 and over with Prader-Willi syndrome. It aims to see if it helps with excessive sleepiness and other behaviors, compared to a dummy pill.
For: Prader-Willi SyndromeUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
This study is looking at a new medicine called vericiguat for children and young people aged 29 days to 17 years with heart failure. We want to see if it can improve their heart health compared to a dummy medicine.
For: Heart Failure · Left Ventricular Systolic DysfunctionUnited States · Belgium · Brazil - Ongoing, recruitingTherapeutic exploratory (Phase II)
Effects of empagliflozin on plasma glucose in patients with HNF1A-MODY: a randomized, double-blind, crossover trial
This study looks at how a drug called empagliflozin (Jardiance) affects blood sugar in people with a specific type of diabetes called HNF1A-MODY. It compares this drug to a dummy pill (placebo) to see if it helps manage blood sugar levels.
For: Maturity-onset diabetes of the young type 3 (HNF1A-MODY)Denmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b Multicenter, Randomized, Double-blind, Placebo-controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-81241459 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis
This study is looking into a new medicine, JNJ-81241459, for people with moderate to severe plaque psoriasis. We want to see how well different doses work to clear up skin patches and if it's safe. It's a key step in developing new treatments.
For: Plaque PsoriasisFrance · Spain · Poland - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
For: Multiple SclerosisUnited States · Argentina · Austria